Your session is about to expire
← Back to Search
Virus Therapy
Vaccinated with polio vaccine (IPV) for COVID-19
Phase 4
Waitlist Available
Research Sponsored by E-MO Biology Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28
Awards & highlights
Study Summary
Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)
Eligible Conditions
- COVID-19
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage of Subjects with Antibodies to SARS-CoV-2 RdRp following IPV Vaccination
Secondary outcome measures
Determination of neutralizing titer of antibodies raised to SARS-CoV-2 following vaccination with polio vaccine
Trial Design
1Treatment groups
Experimental Treatment
Group I: Vaccinated with polio vaccine (IPV)Experimental Treatment1 Intervention
All subjects will receive polio vaccine: IPV as manufactured by Sanofi Pasteur for distribution in the United States
Find a Location
Who is running the clinical trial?
E-MO Biology IncLead Sponsor
John AndrewsStudy ChairE-MO Biology Inc
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger